{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T13:46:29Z","timestamp":1792590389815,"version":"4.5.0"},"reference-count":36,"publisher":"SAGE Publications","issue":"8","license":[{"start":{"date-parts":[[2021,10,6]],"date-time":"2021-10-06T00:00:00Z","timestamp":1633478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Feline Medicine and Surgery"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The aim of this study was to assess the efficacy of a new therapeutic regimen of oclacitinib for the control of feline atopic skin syndrome (FASS) and to correlate plasma levels of this drug with clinical effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Twenty-eight client-owned cats with a clinical diagnosis of FASS were recruited. Oclacitinib was administered at 1 mg\/kg q12h for 2 weeks and then at 1 mg\/kg q24h for a further 2 weeks. At the study outset (D0), and 7 (D7) and 28 (D28) days after starting treatment, clinical lesions were assessed using a validated scoring system (SCORing Feline Allergic Dermatitis [SCORFAD]) and pruritus was graded via an adapted visual analogue scale (PVAS). At the same time points, plasma oclacitinib levels and haematological variables were measured.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 18 cats completing the study, PVAS and SCORFAD improved by \u2a7e50% in 61% and 88% of animals, respectively. Mean PVAS decreased significantly between D0 and D7 and between D0 and D28 (both\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.001) but not between D7 and D28. Likewise, mean SCORFAD values decreased significantly between D0 and D7 and between D0 and D28 (both\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.001) but not between D7 and D28. On D7 and D28, plasma oclacitinib concentrations varied widely from 0 to 1443.2 ng\/ml and from from 0 to 1177.7 ng\/ml, respectively. Oclacitinib concentrations showed no correlation with clinical effects (SCORFAD and PVAS).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and relevance<\/jats:title>\n                    <jats:p>Oclacitinib emerged as being safe and effective to control clinical signs of FASS. A mean dose of 1 mg\/kg, even without extending twice-daily treatment beyond the first 2 weeks, could be a suitable therapeutic regimen. Plasma drug levels did not seem useful to predict clinical response during treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1098612x211048458","type":"journal-article","created":{"date-parts":[[2021,10,8]],"date-time":"2021-10-08T13:28:55Z","timestamp":1633699735000},"page":"787-793","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":11,"title":["Efficacy of oclacitinib for the control of feline atopic skin syndrome: correlating plasma concentrations with clinical response"],"prefix":"10.1177","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5252-8331","authenticated-orcid":false,"given":"Isaac","family":"Carrasco","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Therapeutics and Toxicology, Universitat Autonoma de Barcelona, Campus de Bellaterra, Bellaterra, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lluis","family":"Ferrer","sequence":"additional","affiliation":[{"name":"Department of Animal Medicine and Surgery, Universitat Autonoma de Barcelona, Campus de Bellaterra, Bellaterra, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5219-7552","authenticated-orcid":false,"given":"Anna","family":"Puigdemont","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Therapeutics and Toxicology, Universitat Autonoma de Barcelona, Campus de Bellaterra, Bellaterra, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2021,10,6]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3164.2011.00962.x"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1177\/1098612X12468922"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/vde.12109"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/vde.12899"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/vde.12928"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/vde.12935"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/vde.12696"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/vde.12341"},{"key":"e_1_3_2_10_2","article-title":"Clinical efficacy of sublingual allergen-specific immunotherapy in 22 cats with atopic dermatitis.","volume":"31","author":"Foj R","year":"2020","unstructured":"Foj R, Carrasco I, Clemente F, et al. Clinical efficacy of sublingual allergen-specific immunotherapy in 22 cats with atopic dermatitis. Vet Dermatol 2020; 31: 134\u2013e24.","journal-title":"Vet Dermatol"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3164.2005.00462.x"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ctsap.2006.05.009"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/vde.12933"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3164.2008.00717.x"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3164.2011.00983.x"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02847"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-019-00333-w"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/jvp.12101"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/vde.12047"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/vde.12458"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/vde.12743"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/vde.12852"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/vde.12088"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/vde.12194"},{"key":"e_1_3_2_25_2","unstructured":"Reinero C. An experimental janus kinase (JAK) inhibitor suppresses eosinophilic airway inflammation in experimental feline asthma. Proceedings of the American College of Veterinary Internal Medicine Forum; 2013 June 12\u201315; Seattle WA. New York: Currant Associated 2013 pp 475\u2013476."},{"key":"e_1_3_2_26_2","first-page":"145","article-title":"The use of oclacitinib (Apoquel\u00ae; Zoetis) for treatment of cutaneous mastocytosis in a cat [abstract].","volume":"25","author":"Frank RK","year":"2014","unstructured":"Frank RK, Galvan BA, Schoell RA, et al. The use of oclacitinib (Apoquel\u00ae; Zoetis) for treatment of cutaneous mastocytosis in a cat [abstract]. Vet Dermatol 2014; 25: 145\u2013162.","journal-title":"Vet Dermatol"},{"key":"e_1_3_2_27_2","first-page":"133","article-title":"Feline idiopathic ulcerative dermatosis treated successfully with oclacitinib [abstract]","volume":"26","author":"Loft K","year":"2015","unstructured":"Loft K, Simon B. Feline idiopathic ulcerative dermatosis treated successfully with oclacitinib [abstract]. Vet Dermatol 2015; 26: 133\u2013159.","journal-title":"Vet Dermatol"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/vde.12949"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/vde.12218"},{"key":"e_1_3_2_30_2","article-title":"A double-blinded, randomized, methylprednisolone-controlled study on the efficacy of oclacitinib in the management of pruritus in cats with nonflea nonfood-induced hypersensitivity dermatitis.","volume":"30","author":"Noli C","year":"2019","unstructured":"Noli C, Matricoti I, Schievano C. A double-blinded, randomized, methylprednisolone-controlled study on the efficacy of oclacitinib in the management of pruritus in cats with nonflea nonfood-induced hypersensitivity dermatitis. Vet Dermatol 2019; 30: 110\u2013e30.","journal-title":"Vet Dermatol"},{"key":"e_1_3_2_31_2","first-page":"6","article-title":"Head and neck feline dermatitis: response to oclacitinib treatment [abstract].","volume":"27","author":"Pandolfi P","year":"2016","unstructured":"Pandolfi P, Beccati M. Head and neck feline dermatitis: response to oclacitinib treatment [abstract]. Vet Dermatol 2016; 27 Suppl 1: 6\u2013121.","journal-title":"Vet Dermatol"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/vde.12819"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3164.2012.01071.x"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3164.2008.00728.x"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/jvp.12087"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12917-019-1893-x"},{"key":"e_1_3_2_37_2","first-page":"374","article-title":"Eficacia do oclacitinib no manejo da s\u0131ndrome da atopia felina.","volume":"47","author":"Fernandes KSBR","year":"2019","unstructured":"Fernandes KSBR, Ferreira MB, da Silva AM, et al. Eficacia do oclacitinib no manejo da s\u0131ndrome da atopia felina. Acta Sci Vet 2019; 47: 374\u2013379.","journal-title":"Acta Sci Vet"}],"container-title":["Journal of Feline Medicine and Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1098612X211048458","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1098612X211048458","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1098612X211048458","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T13:20:31Z","timestamp":1792588831000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1098612X211048458"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,6]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["10.1177\/1098612X211048458"],"URL":"https:\/\/doi.org\/10.1177\/1098612x211048458","relation":{},"ISSN":["1098-612X","1532-2750"],"issn-type":[{"value":"1098-612X","type":"print"},{"value":"1532-2750","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,6]]}}}